The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Long-term outcomes of neoadjuvant DCF in locally advanced ESCC
Ken Kato, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, discusses the 5-year follow-up results from the JCOG1109 study (jRCTs031180202) of neoadjuvant 5- fluorouracil plus cisplatin (CF) with or without docetaxel (DCF) in patients with locally advanced esophageal squamous cell cancer (ESCC). Addition of docetaxel significantly improved overall survival (OS) and progression-free survival (PFS). The study highlights sustained clinical benefits and manageable safety profile of CF with docetaxel. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers’ Bureau – Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding – AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
